Q3 2025 Corcept Therapeutics Inc Earnings Call Transcript
Key Points
- Corcept Therapeutics Inc (CORT) reported a revenue increase to $207.6 million in Q3 2025, up from $182.5 million in the same period last year.
- The company has expanded its prescriber base significantly over the last two years, contributing to robust growth in its hypercortisolism business.
- Corcept Therapeutics Inc (CORT) is transitioning to a new pharmacy with greater capacity to meet increasing demand, and plans to add additional pharmacies to support future growth.
- The CATALYST study results, published in a leading journal, have increased physician awareness of hypercortisolism, potentially expanding the market for Corcept's treatments.
- Corcept Therapeutics Inc (CORT) is on track for FDA approval of relacorilant for hypercortisolism by December 30, 2025, and for platinum-resistant ovarian cancer by July 11, 2026.
- Net income for Q3 2025 decreased to $19.7 million from $47.2 million in the same quarter last year.
- The company is still facing patent litigation with Teva Pharmaceuticals, which could impact future revenue if not resolved favorably.
- Capacity constraints with the previous pharmacy vendor have affected the ability to fully capitalize on the surge in demand.
- Despite the strong results from the ROSELLA trial, Corcept Therapeutics Inc (CORT) did not receive a priority review from the FDA for its ovarian cancer NDA.
- The transition to a new pharmacy and the onboarding of additional pharmacies may lead to temporary disruptions in service and fulfillment.
Thank you for standing by, and welcome to Corcept Therapeutics third-quarter 2025 earnings conference call. (Operator Instructions) I would now like to hand the call over to Atabak Mokari, CFO. Please go ahead.
Hello, everyone. Good afternoon, and thank you for joining us. Today, we issued a press release announcing our financial results for the third quarter and providing a corporate update. A copy is available at corcept.com. Our complete financial results will be available when we file our Form 10-Q with the SEC.
Today's call is being recorded. A replay will be available at the Investors Past Events tab of our website. We will also post a presentation regarding our oncology development programs in the same section.
Statements during this call other than statements of historical fact are forward-looking statements based on our plans and expectations that are subject to risks and uncertainties, which might cause actual results to be materially different from those
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
